Vesicular stomatitis virus (VSV) is a promising vector for vaccine and oncolysis, but it can also produce acute diseases in cattle, horses, and swine characterized by vesiculation and ulceration of the tongue, oral tissues, feet, and teats. In experimental animals (primates, rats, and mice), VSV has been shown to lead to neurotoxicities, such as hind limb paralysis. The virus matrix protein (M) and glycoprotein (G) are both major pathogenic determinants of wild-type VSV and have been the major targets for the production of attenuated strains. Existing strategies for attenuation included: (1) deletion or M51R substitution in the M protein (VSV M51 or VSVM51R, respectively); (2) truncation of the C-terminus of the G protein (G 28). Despite these mutations, recombinant VSV with mutated M protein is only moderately attenuated in animals, whereas there are no detailed reports to determine the pathogenicity of recombinant VSV with truncated G protein at high dose. Thus, a novel recombinant VSV (VSV M51-G 28) as well as other attenuated VSVs (VSV M51, VSV-G 28) were produced to determine their efficacy as vaccine vectors with low pathogenicity. In vitro studies indicated that truncated G protein (G 28) could play a more important role than deletion of M51 ( M51) for attenuation of recombinant VSV. VSV M51-G 28 was determined to be the most attenuated virus with low pathogenicity in mice, with VSV-G 28 also showing relatively reduced pathogenicity. Further, neutralizing antibodies stimulated by VSV-G 28 proved to be significantly higher than in mice treated with VSV M51-G 28. In conclusion, among different attenuated VSVs with mutated M and/or G proteins, recombinant VSV with only truncated G protein (VSV-G 28) demonstrated ideal balance between pathogenesis and stimulating a protective immune response. These properties make VSV-G 28 a promising vaccine vector and vaccine candidate for preventing vesicular stomatitis disease.
Introduction
Vesicular stomatitis virus (VSV) is a single-strained negativesense RNA virus that has been widely used as a vector for vaccine development [1, 2] . Recombinant VSV can accommodate large and multiple foreign genes in its genome that are expressed at high levels [3] and confer advantages over other RNA viral vectors. Due to its potent capabilities in triggering cellular, humoral, and mucosal immunities in animals, even after a single administration, recombinant VSV has been studied as a vaccine vector not only for preventing vesicular stomatitis disease in livestock [4] , but a number of human pathogens including: Influenza virus, Ebola virus, Marburg virus, Human immunodeficiency (HIV) virus, Severe Acute Respiratory Syndrome (SARS) virus, and Hepatitis C virus [5] [6] [7] [8] [9] .
However, VSV is a notoriously infectious agent that not only produces acute disease, such as vesicular lesions in cattle, swine and horses, but neurotoxicity in experimental animals, including primates and mice [10] [11] [12] . Therefore, modifications are needed to improve the safety of VSV before it can be applied clinically as a replication competent vector.
VSV genomic RNA is transcribed into five capped and polyadenylated mRNAs by the viral RNA-dependent RNA polymerase. The mRNAs encode five structural proteins: nucleocapsid protein (N); phosphoprotein (P), which is a cofactor of the RNA-dependent RNA polymerase (L); matrix protein (M); and attachment glycoprotein (G) [12] . M and G proteins are both primary pathogenic determinants of VSV [13, 14] . The M protein is a multi-functional protein involved in virus assembly, budding and pathogenesis [15, 16] , and capable of inhibiting the transport of host mRNAs out of the nucleus significantly inhibiting type I interferon (IFN) signaling [17] . The G protein is responsible for viral binding to the host receptor and entry of VSV into host cells and its cytoplasmic domain is 0264-410X/$ -see front matter © 2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.vaccine.2011.12.085 considered to play an important role in viral budding and packaging [18] [19] [20] .
To date, several strategies have focused on the M or G proteins for the generation of attenuated VSV. It was reported that deletion of methionine residue 51 (VSV M51) or M51R substitution (VSVM51R) within the M protein can lead to attenuation due to the potent induction of type I IFN [17, 21] . Another attenuation strategy is dependent upon truncation within the C-terminal region of the G protein (VSV-G 28) that significantly impacts viral budding and packaging efficiency [22] . In vivo, however, VSV M protein mutant proved to be only moderately attenuated in experimental infections [16, 21] , whereas there is currently no information available if recombinant VSV with truncated G protein is safe or not when animals challenged with high dose of the mutant virus.
The current study developed a novel recombinant VSV (VSV M51-G 28) with mutations in both M and G proteins, including deletion of methionine 51 in the M protein and a truncation of 28 amino acids in C-terminal region of the G protein. It was hypothesized that VSV M51-G 28 could combine the advantages observed for the M51 and G 28 mutations to produce a safer and more effective vaccine vector. Furthermore, for the first time, different attenuated VSVs with mutated M and/or G proteins were comprehensively compared in vitro and in vivo. Based on pathogenicity and capabilities to stimulate potent immune responses, we aimed to identify a suitable recombinant VSV vaccine vector and vaccine candidate for preventing vesicular stomatitis disease.
Materials and methods

Plasmid construction and rescue of recombinant VSVs
The recombinant VSVs rescued in our study were based on the infectious clone, VSV Indiana [1] . The plasmid pVSV M51 was kindly provided by Prof. John Bell (Univ. of Ottawa, Canada). The pVSV XN2 and helper plasmids, pBS-N, P, L, were provided by Prof. Glen Barber's Lab (Univ. of Miami, USA). The pVSV-G 28 and pVSV M51-G 28 were constructed based on pVSV XN2 and pVSV M51, respectively. In the constructs, the wild-type VSV G protein cytoplasmic tail (29 aa) was truncated with only one arginine residue remaining in the tail (G 28) (Fig. 1) . The forward primer used for polymerase chain reaction (PCR) amplification of G 28 was: 5 -CCGGAGCGCTATGAAGTGCCTTTTGTACTTA-3 (underlined indicates the MluI restriction site), and the reverse primer was: 5 -CC-GGCTCGAGCGTGATATCTGTTAGTTTTTTTCATACCTAGCAGGATTTG-AGTCATTATCGGGAGAACCAAGAATAG-3 (underlined indicates the XhoI restriction site and bold residues indicate the two tandem repeat stop codons). To construct pVSV-G 28 or pVSV M51-G 28, VSV G gene of pVSV XN2 or pVSV M51 was substituted with G 28 by restriction digestion with MluI and XhoI. All the start/stop signals for viral gene transcription were preserved. A schematic representation of pVSV M51-G 28 is shown in Fig. 1 .
Recovery of recombinant VSVs from the infectious clones was performed as previously described [3] . Briefly, co-transfection of VSV constructs (pVSV M51, pVSV-G 28, pVSV M51-G 28) with helper plasmids, pBS-N, P, and L, was performed into BHK21 cells infected with a recombinant vaccinia virus (vTF7-3) expressing T7 RNA polymerase. At 48 h post-transfection, culture supernatants were collected and filtered through a 0.2 M filter into fresh BHK21 cells. Cells were checked daily. If typical cytopathic effect (CPE) was observed 2-3 days after VSV infection, supernatants were collected and viruses were plaque-purified in Vero cells. Individual plaques were isolated and seed stocks were amplified in BHK21 cells. Recombinant viruses were concentrated by ultracentrifugation at 30,000 rpm/min for 2 h and frozen at −70 • C. Viral titer was determined by plaque assay performed in Vero cells. VSV XN2 with wild-type G (wt G) and M proteins was prepared from the stock kept in our laboratory.
Analysis of proteins synthesis
To identify rescued recombinant VSVs, western blot was used to identify typical bands for L, G, N/P, and M proteins using specific convalescent sera from VSV XN2 -infected mice. In short, confluent BHK21 cells were infected with VSV M51, VSV G 28 or VSV M51-G 28 at a multiplicity of infection (MOI) of 1. VSV XN2 was used as a control. At 24 h post-infection (p.i.), cells were lysed in buffer containing 5% ␤-mercaptoethanol, 0.01% NP-40, and 2% sodium dodecyl sulfate (SDS). Proteins were separated by 12% SDS polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane (Thermo Scientific, Rockford, IL, USA) in a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad, Hercules, CA, USA). Sera from a VSV XN2 infected mouse was used as the primary antibody at a dilution of 1:2000 with horseradish peroxidase-conjugated goat anti-mouse IgG as the secondary antibody at a dilution of 1:5000 (Santa Cruz, CA, USA). Target bands were observed using West Pico Chemiluminescent Substrate (Thermo Scientific) and exposed to Kodak BioMax MR film (Kodak, Rochester, NY, USA).
Plaque forming characterization of recombinant VSVs
Attenuation of virus could be characterized by analyzing plaque formation sizes in cells [16] . The A549 cell line was used as a type I IFN signaling competent cell line [23] , whereas Vero cells were used as an incompetent cell line [24, 25] . Plaque formation experiments were set up in these cells to identify the role by type I IFNs in viral attenuation. Briefly, 90% confluent A549 or Vero cells in 12-well plates were infected with optimally diluted VSV M51-G 28,VSV M51, VSV G 28, or VSV XN2 and then covered with low melting temperature agar (Invitrogen, Carlsbad, CA, USA) after rinsing with phosphate buffered saline (PBS). At 24 h p.i., 1% crystal violet was used to stain Vero cells, whereas A549 cells were stained 48 h p.i. Plaques were first scanned with Gel Imager (Tanon-1600R, Tanon, Shanghai, China) under bright light and then individual plaques were viewed and photographed under 4× magnification using a microscope (Nikon, Tokyo, Japan) equipped with a digital camera. The mean plaque size was determined by measuring the area of each plaque in each group using Nikon NIS-Elements BR software (Nikon).
Multi-step growth curves by different VSVs and IFN-ˇ assay
The human prostate cancer cell line, PC3, was used as another cell line with competent type I IFN signaling [17] . At 70% confluency, PC3 cells in 24-well plates were infected with viruses at a low MOI of 0.01. After 1 h of absorption, the inoculum was removed and cells were washed three times with PBS, fresh Dulbecco's modified Eagle's medium (DMEM supplemented with 2% fetal bovine serum) was added, and the infected cells were incubated at 37 • C. Aliquots of cell culture supernatants were removed at 24, 48, and 72 h p.i. Viral titers in supernatants were detected by plaque assays in Vero cells. The harvests at 24 h p.i. were also assayed for IFN-␤ level using the Human Interferon-␤ ELISA Kit (R&D Systems, Minneapolis, MN, USA).
Pathogenesis of mutated VSVs
Specific pathogen free (SPF) female BALB/c mice (∼20 g body weight) were purchased from Shanghai SLAC Experimental Animal Company (Chinese Academy of Sciences, China) and divided into five groups (10 per group) inoculated intranasally with VSV M51-G 28, VSV-G 28, VSV M51, VSV XN2 , or PBS under light anesthesia with ketamine-xylazine. The inoculated dose of different VSVs was 10 7 plaque-forming units (PFU) in 20 L of PBS; the highest dose that could be prepared by ultracentrifugation for VSV-G 28 or VSV M51-G 28. Animal body weight losses and survival were monitored every day until 14 days p.i. All animal studies were performed in accordance with a protocol approved by the Shanghai JiaoTong University Experimental Animal Center.
Recovery of recombinant VSVs in brain
Since wild-type VSV possesses neurotropism that could lead to serious neurotoxicities in animals, recovery of VSV in brain tissues was performed to identify the associations of pathogenesis with viral replications in host. In short, SPF mice were divided into five groups and were challenged intranasally with VSV XN2 , VSV M51, VSVG 28 or VSV M51-G 28 at a dose of 10 7 PFU, and the control group with PBS. In each group, two mice were sacrificed at 2 and 5 days post-inoculation and their brains were removed for viral detection. Tissues were weighed in 2 mL cell frozen vials, quickly frozen in liquid nitrogen and then kept under −70 • C. For viral assay, tissues were thawed and suspended in 1 mL PBS and then completely homogenized using a Dounce homogenizer. The homogenized tissues were centrifuged at 10,000 rpm for 5 min and the suspensions were serially diluted in PBS. Viral titers were determined by standard plaque assays in Vero cells, as described above. Plaques were observed and counted after 24 h incubation.
Neutralizing antibody after immunization with mutated VSVs
Immune responses induced by VSV M51-G 28 or VSV-G 28 were evaluated in BALB/c mice (∼20 g each). Female SPF BALB/c mice were divided into three groups and immunized with VSV M51-G 28, VSV-G 28 or PBS as the control. Animals in VSV M51-G 28 or VSV-G 28 treated groups were further divided into two subgroups (five per subgroup) that were housed in isolation hutches and intranasally inoculated once with viruses at doses of 10 3 PFU or 10 4 PFU in 20 L PBS. Blood was collected from anesthetized mice by retro-orbital bleeds before and 21 days after vaccinations. The vaccinated mice were then challenged with VSV XN2 . Blood was allowed to clot at room temperature and sera were collected after centrifugation, and stored at −80 • C for neutralization assays.
Sera from animals were heat inactivated at 56 • C for 30 min. Those from VSV vaccinated animals were serially diluted two-fold in DMEM starting at 1:5. For determination of neutralizing antibody titer, 50 L of the diluted sera were then mixed with 100 PFU VSV XN2 in 50 L DMEM. The mixtures were incubated for 1 h at 37 • C before being added to 60-70% confluent BHK21 cells. Cells were incubated at 37 • C for at least 2-3 days and checked for CPE. Additionally, 50 L sera from PBS treated animals were directly combined with 100 PFU/50 L VSV XN2 and treated as for other sera. For titer determination, the reciprocal of the dilution giving a 100% inhibition of CPE was recorded.
Virus challenge
At 21 days after immunization, all mice were intranasally administered 10 7 PFU VSV XN2 in 20 L of PBS. Animals were observed every day to calculate survival curves and body weight loss, as previously described.
Statistical analysis
Plaque areas, IFN-␤ concentrations, and body weight loss among different groups were compared by Student's t-test, with a twotailed distribution using the statistical features in Microsoft Excel (Microsoft, Redmond, WA, USA).
Results
Construction of recombinant VSVs with mutated M or/and G proteins
All viruses rescued in the current study were based on the VSV Indiana infectious clone [1] . To construct safer recombinant VSV, VSV M51-G 28 was successfully generated that, for the first time, incorporated double mutations in M and G proteins. The novel virus and other attenuated VSV (VSV M51, VSV-G 28) were identified through western blotting with convalescent serum from mice infected with VSV XN2 was used as the wild-type VSV control. Bands representing VSV structural proteins were identified (Fig. 2) . It was proved that although length of G protein cytoplasmic domain was critical for viral budding and packaging [19] , we did find that with only one arginine residue remaining in the G protein cytoplasmic domain, VSV could still be rescued. In comparison with wild-type VSV G protein, a low molecular weight band presumed to be the G 28 was detected (Fig. 2 ). Viral RNA of the different recombinant VSVs (VSV M51-G 28, VSV M51, and VSV-G 28) were extracted and reverse-transcription (RT)-PCR was used to amplify viral M or G genes. The PCR products were sequenced for mutations occurring in M and G genes (data not shown).
Attenuation of VSV
Two methods were used to assess attenuation of VSV M51-G 28, which included plaque formation size and multi-cycle growth curves in type I IFN signaling competent cells (A549, PC3) [17, 23] or incompetent cells (Vero) [24, 25] . The results were compared to those produced by other recombinant VSVs. Crystal violet stained plaque sizes were determined for Vero or A549 cells infected with different VSVs (Figs. 3a and 4a) . In Vero cells, the average plaque sizes (n = 10) between VSVs with wt G (VSV XN2 and VSV M51) were similar (p > 0.05), but both were significantly larger than those containing the G 28 mutation (VSV-G 28 or VSV M51-G 28) (p < 0.01; Fig. 3a and b) . Average plaque sizes for VSV-G 28 and VSV M51-G 28 were comparable. These data indicated that, in type I IFN signaling incompetent Vero cells, G 28 but not M51 was involved in VSV attenuation.
In A549 cells, the average plaque areas produced by VSV XN2 were much larger than those by VSV M51, however, areas by VSV M51 was also larger than VSV-G 28 (p < 0.01; Fig. 4a and b) . The smallest and turbid plaques were formed by VSV M51-G 28 in A549 cells and were difficult to detect. Based on these results, both G 28 and M51 assist the attenuation of VSVs in type I IFN signaling competent A549 cell and the attenuation tendencies as follows: VSV XN2 > VSV M51 > VSV-G 28 > VSV M51-G 28.
PC3 was also used in the current study as a type I IFN signaling competent cell line [17] . To quantify the relationship between amount of VSV-induced type I IFN and viral replication titers, multicycle growth curves were performed with inoculation of viruses at low MOI of 0.01. As shown in Fig. 5a , titers of VSV M51-G 28 reached the highest levels at 24 h p.i., but only around 5 × 10 3 PFU/mL and decline thereafter. VSV M51 also reached the IFN-␤ levels in VSV-treated PC3 cells were quantified at 24 h p.i. to identify the role by type I IFNs. In different recombinant VSV-infected PC3 cells, induction of IFN-␤ was inversely correlated with viral replication titers. As shown in Fig. 5b , the high levels of IFN ␤ were induced in M51 VSV-treated cells. In VSV M51 infected cells, IFN-␤ concentrations reached ∼2000 pg/mL, but the highest replication titer was ∼2 orders of magnitude lower than for VSV XN2 . Although IFN-␤ production in VSV M51-G 28 treated cells was as low as ∼300 pg/mL, this was still significantly higher than VSV XN2 (p < 0.05). IFN-␤ detected in the supernatants of VSV-G 28 treated cells was below the limit of detection for the assay. Therefore, viral attenuation showed the following trends: VSV XN2 > VSV M51 > VSV-G 28 > VSV M51-G 28. Importantly, the fact that M51 led to attenuation of VSV through the induction of antiviral IFNs was proved again in our study.
Based on the above data, both G 28 and M51 were shown to be involved in the attenuation of VSV, however, G 28 could play a more important role than M51. Regardless, the double mutation VSV, VSV M51-G 28, showed the most significant attenuation in vitro.
VSV M51 was not as safe as VSVs containing truncated G proteins in vivo
The current study investigated the pathogenesis of VSV M51-G 28 in BALB/c mice and compared with other attenuated VSV or VSV XN2 as the wild-type virus control. Inoculation of VSV through intranasal has been proven to be the most sensitive way to evaluate pathogenesis by VSV [10, 22] . A challenge dose of 10 5 -10 6 PFU wild-type VSV has been previously shown to result in significant mortality in BALB/c mice [10] . Therefore, in our studies, SPF BALB/c mice were inoculated intranasally with different recombinant VSVs at a dose of 10 7 PFU/20 L; the maximum dose that could be prepare for concentrated VSV-G 28 or VSV M51-G 28 in a 20 L volume. Body weight and survival curve were used as indications of pathogenesis and monitored every day for 14 days p.i.
As shown in Fig. 6a , the body weight of naïve mice treated with VSV M51-G 28 or VSV-G 28 increased steadily post infection without death, similar to the PBS group. However, in the VSV XN2 treated group, mice lost significant body weight (∼30%) and neurotoxicities were evident in some animals ( Fig. 6a and c) with all animals dying at around 6 days p.i. (Fig. 6b) . VSV M51 showed moderate attenuation compared with VSV XN2 , but infected mice still showed significant loss of body weight with 40% mortality.
Wild-type VSV possesses neurotropism in many animals, including primates, rats, and mice that can lead to serious neurological deficits, such as hind limb paralysis. To identify the association of pathogenesis with viral replication, naïve mice were inoculated intranasally with different VSVs at a dose of 10 7 PFU. Viruses isolated from the brains of animals were screened by plaque assay at 2 and 5 days p.i. As shown in Table 1 , VSV XN2 treated mice showed viral titers up to 4 × 10 5 PFU/g at 2 days p.i and 1.6 × 10 3 PFU/g at 5 days p.i. Although much lower than VSV XN2 , viral titers detected in brain tissues from VSV M51 infected mice were determined to be 3.5 × 10 2 PFU/g at 2 days p.i., but no virus was detected at 5 days p.i. In VSV M51-G 28 and VSV-G 28 treated mice, no virus could be detected in brain tissues at the two time points, which could explain why animal body weight kept steadily increased over the duration of the study in these groups. Therefore, this study showed that virulence of different VSVs was closely related to replication levels in the target organ, namely the brain. VSV M51 was not as safe as those with truncated G proteins in vivo. VSV M51-G 28 and VSV-G 28 were attenuated enough as vaccine vectors.
VSV-G 28 induced a more potent protective immune response than VSV M51-G 28
Recombinant VSVs with truncated G protein (VSV M51-G 28, VSV-G 28) have been proved to be significantly attenuated both in vitro and in vivo, whereas the attenuation of the viral vector was often associated with the loss of vector immunogenicity. Therefore, an ideal viral vector should retain both essential characteristics to be considered safe and effective.
To evaluate protective immunity stimulated by VSV M51-G 28 or VSV-G 28 in vivo, SPF mice were immunized at different doses and then challenged with a lethal dose of VSV XN2 . Blood was taken before and 21 days post immunization for neutralization antibody assays. As shown in Fig. 7 , the VSV M51-G 28 immunized group immunized with 10 4 PFU showed survival of all animals after challenge (Fig. 7a) , however, mice still lost body weight up to ∼20%. At an immunization dose of 10 3 PFU, 40% of animals died at around 6 days post-challenge and all animals suffered serious body weight loss up to 25% and recovered very slowly (Fig. 7b) . In mice immunized with VSV-G 28 at doses of 10 3 or 10 4 PFU, the body weights of all animals increased steadily after challenge with no death and significant body weight loss. All animals in PBS control group died at 6 days post-challenge (Fig. 7c) . Therefore, these data suggested that VSV-G 28 could stimulate more potent protective immunities than VSV M51-G 28.
To further characterize the protective response, neutralization antibodies developed in the vaccinated animals were assayed. As shown in Table 2 , no antibody titer could be detected in animals before vaccination and PBS treated mice. It was determined that the antibody titer generated by immunization with VSV-G 28 against the parental, VSV Indiana , was significantly higher than those produced by VSV M51-G 28 immunization. In VSV-G 28 groups, antibody titers were 320-640 at a vaccination dose of 10 3 PFU and 640-1280 at 10 4 PFU. However, in the VSV M51-G 28 group with a dose of 10 3 PFU, antibody titer was only 10-20 and all mice with a titer of 10 died post-challenge (Fig. 7b) indicating that the titer was unable to protect animals. Moreover, even animals vaccinated at 10 4 PFU, antibody titer only reached 40-80. Based on these results, it could be concluded that VSV-G 28 could stimulate a more potent protective humoral immune response than VSV M51-G 28, which might be due to the extreme attenuation of VSV M51-G 28 in vivo. As a result, VSV-G 28 may attain an ideal balance between pathogenesis and stimulating a protective immune response and with the potential as a vaccine vector and vaccine candidate for vesicular stomatitis disease.
Discussion
Replication-competent viruses with little or no pathogenesis have been important alternatives for developing vaccines or vaccine vectors due to their capabilities in stimulating potent and comprehensive immunity in vivo. However, safety and efficacy are equally important criteria. Traditionally, the isolation of spontaneously attenuated virus in host or serial passages of wild-type virus in a non-natural host were important methods to acquire attenuated viruses. With the development of molecular technology, the construction of recombinant viruses based on reverse genetics, have become common for developing novel viral vectors. VSV is a promising vector for both vaccination and oncolysis, but still has not been applied clinically. One of the main reasons lies in its potential pathogenesis in humans and animals. Rearrangement of structural protein genes [26] and mutations in M or G proteins are existing strategies to generate attenuated VSV that are replication competent.
Our study focused on the two pathogenic proteins of VSV, M and G proteins, for the purposes of: (1) making a safer VSV; (2) Table 1 Recombinant VSVs recovered from brain tissues of mice (PFU/g). Naïve mice were inoculated with recombinant VSVs including VSVXN2, VSV M51,VSV-G 28,VSV M51-G 28 or PBS as a control. The brains of two mice were removed at 2 or 5 days post-inoculation. Homogenized brains were assayed for viral titers and the mean values were calculated. ND: not detected. VSV M51 was attenuated in vivo. On the other hand, VSV is an enveloped virus that is released via budding from host cell membranes. Previous studies have noted that the length of cytoplasmic domain on VSV G, not the specific sequence, was required for efficient viral budding [19] . The real role of truncated G protein in attenuation of VSV has still not been identified, although it was reported that VSV C-terminal truncated G proteins acquired complex oligosaccharides ∼6-fold slower than for wt G protein and displayed a reduced rate of transport from the endoplasmic reticulum to the Golgi apparatus, and presumably to the cell surface [18] .
Inoculum
Through in vitro assays in type I IFN signaling competent cells/incompetent cells, both M51 and G 28 were proven to be important for VSV attenuation. In Vero cells, G 28 but not M51, was involved in VSV attenuation. Recombinant VSV with G 28 was shown to form significantly smaller plaques than virus with wild-type G, whereas plaque sizes between VSV XN2 and VSV M51 or those between VSV-G 28 and VSV M51-G 28 were similar, no matter whether M protein was mutated or not. However, in A549 cells with effective type I IFN signaling, attenuation tendencies were demonstrated follow these tendencies: VSV XN2 > VSV M51 > VSV-G 28 > VSV M51-G 28. This tendency was also proven in PC3 cells through multi-cycle growth curve characterization. The replication titers of different VSVs were shown to be inversely correlated with the expression levels of type I IFNs. VSV M51-G 28 formed the smallest plaque in A549 cells and lowest titer in PC3 cells among all VSVs tested in the current study due to the double mutations in M and G proteins. This study developed two main conclusions both in vitro and in vivo studies:
(1) Both G 28 and M51 mutations assisted attenuation of VSV, and (2) G 28 could play a more important role than M51 for attenuation. Therefore, VSV M51 was not suitable as a vaccine vector due to its potential pathogenesis in animals and safety is the most important criteria for developing a vaccine or vaccine vector. On the other hand, VSV M51 may be suitable for virotherapy, as many studies have attempted [27, 28] , since, (1) efficacy is a priority as an antitumor drug and (2) many types of tumor cells are type I IFNs signaling defective [29] . Therefore, as an oncolytic virus, VSV M51 could replicate selectively and potently in tumor cells, but rarely in normal cells with competent type I IFN signaling.
An ideal replication competent vaccine vector should possess a suitable balance between pathogenesis and capability to stimulate immunity effectively. Both VSV-G 28 and VSV M51-G 28 have demonstrated significant attenuation compared to VSV XN2 or VSV M51, which are considered safe as vaccine vectors. However, we sought to determine which attenuated virus would work better in stimulating potent protective immunities that are critical for their clinical applications. To evaluate protective immunities stimulated by VSV-G 28 and VSV M51-G 28, animals were immunized with different doses of viruses and then challenged with a lethal dose of VSV XN2 , which is the "gold standard" to evaluate efficacy of a VSV vaccine. As shown in the current study, VSV-G 28 could stimulate more potent protective immunities than VSV M51-G 28. Of note, VSV-G 28 treated animals inoculated with a low 10 3 PFU dose, no deaths or significant body weight losses were observed post-challenge with VSV XN2 . However, animals in VSV M51-G 28 treated group suffered serious body weight loss even when immunized with 10 4 PFU and some Table 2 Serum neutralizing antibody titers in mice against VSV Indianna after inoculation with VSV-G 28 or VSV M51-G 28. Animals were inoculated with 10 3 or 10 4 PFU of different VSVs with PBS as a control. Sera were collected before and 21 days after inoculation. Neutralizing antibody titers against VSV Indiana were determined and expressed as the reciprocal of the highest dilution of antibody giving a 100% inhibition of cytopathic effect. '-': not detectable. animals died when the dose was as low as 10 3 PFU. The results correlated with neutralization antibody titers stimulated by different VSVs. Neutralization antibodies titers in animals vaccinated with VSV-G 28 were shown to be much higher than those with VSV M51-G 28. Therefore, although VSV M51-G 28 contained the double mutated M and G proteins and was a very safe viral vector, it was not as effective as VSV-G 28 in stimulating protective immunity, possibly due to its extreme attenuation in vivo. In summary, among different attenuated VSVs with mutated M or/and G proteins, recombinant VSV with only truncated G protein (VSV-G 28) indicated ideal balance between pathogenesis and capabilities in stimulating protective immune response and could be a promising vaccine vector. However, for the purpose of developing a vaccine candidate for the prevention of a VSV pandemic, these vaccine candidates would need to be evaluated in swine and cattle, which are the natural host of VSV, before its application in the field.
Recombinant
Conclusions
In the current study, a novel recombinant VSV was constructed with mutations in both M ( M51) and G (G 28) proteins. For the first time, VSV with mutated M and/or G proteins (VSV M51, VSV-G 28, VSV M51-G 28) were compared to evaluate their potentials as vaccine vectors. The experimental conclusions included: (1) both G 28 and M51 contribute to the attenuation of VSV, however, G 28 is likely to play a more important role than M51. VSV M51-G 28 was determined to show the most significant attenuation in vitro. 
